Tag: skin rash

Approval based on pivotal results showing improvements in sustained disease remission and reductions in itch and oral corticosteroid use compared to placebo in adults with BP

New late-breaking data at EAACI showed Dupixent outperformed Xolair across all primary and secondary efficacy endpoints of CRSwNP and in all asthma-related endpoints

Atopic dermatitis is a chronic disease that disproportionately impacts communities of color

MIAMI, June 06, 2025 (GLOBE NEWSWIRE) -- RESTEM – a clinical-stage biotechnology company that develops off-the-shelf, next-generation cell therapies designed to modulate the immune system, today announced that it will present the rationale and study design of its Phase 2/3 IIMPACT (Idiopathic Inflammatory Myopathy Phase 2/3 Adaptive Clinical Trial) trial of Restem-L, the Company’s umbilical-lining modified progenitor cells (UMPC) program for the treatment of Polymyositis and Dermatomyositis (PM/DM), a rare autoimmune disease, now defined by the FDA as Idiopathic Inflammatory Myopathy (IIM). The oral presentation will be delivered at the European Alliance of Associations for Rheumatology's (EULAR) 2025 Congress, to take place June 11-14 in Barcelona, Spain.